Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).

Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M.

Oncology. 2011;80(1-2):70-5. doi: 10.1159/000328739. Epub 2011 Jun 9.

PMID:
21659785
2.

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.

Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y.

Acta Oncol. 2012 Sep;51(7):867-72. doi: 10.3109/0284186X.2012.682629. Epub 2012 May 4.

PMID:
22554343
3.

Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.

Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K.

Ann Oncol. 2006 Jun;17(6):968-73. Epub 2006 Apr 7.

PMID:
16603600
4.

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.

Lancet Oncol. 2010 Sep;11(9):853-60. doi: 10.1016/S1470-2045(10)70181-9. Epub 2010 Aug 12.

PMID:
20708966
5.

A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.

Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63. doi: 10.1007/s00280-013-2143-8. Epub 2013 Mar 31.

PMID:
23543294
6.

[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].

Komatsu Y, Yuki S, Tateyama M, Kudo M, Asaka M.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:131-4. Japanese.

PMID:
16897988
7.

Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.

Kusaba H, Esaki T, Futami K, Tanaka S, Fujishima H, Mitsugi K, Sakai K, Ariyama H, Tanaka R, Kinugawa N, Ueki T, Mibu R, Baba E, Nakano S, Akashi K.

Cancer Sci. 2010 Dec;101(12):2591-5. doi: 10.1111/j.1349-7006.2010.01728.x. Epub 2010 Sep 24.

8.

Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.

Higashi D, Egawa Y, Hirano Y, Hirano K, Miyake T, Takahashi H, Uwatoko S, Abe S, Yamamoto S, Mikami K, Futami K, Maekawa T, Inoue R, Miyazaki M.

Anticancer Res. 2014 Aug;34(8):4595-9.

PMID:
25075105
9.

Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.

Takaoka T, Kimura T, Shimoyama R, Kawamoto S, Sakamoto K, Goda F, Miyamoto H, Negoro Y, Tsuji A, Yoshizaki K, Goji T, Kitamura S, Yano H, Okamoto K, Kimura M, Okahisa T, Muguruma N, Niitsu Y, Takayama T.

Cancer Chemother Pharmacol. 2016 Aug;78(2):397-403. doi: 10.1007/s00280-016-3096-5. Epub 2016 Jun 24.

PMID:
27342247
10.

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).

Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y.

Int J Clin Oncol. 2016 Aug;21(4):705-712. doi: 10.1007/s10147-015-0943-z. Epub 2016 Jan 8. Erratum in: Int J Clin Oncol. 2017 Nov 14;:.

PMID:
26746689
11.

Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.

Otsuka H, Fujii T, Toh U, Iwakuma N, Takahashi R, Mishima M, Takenaka M, Kakuma T, Tanaka M, Shirouzu K.

Breast Cancer. 2015 Jul;22(4):335-42. doi: 10.1007/s12282-013-0483-1. Epub 2013 Jul 5.

PMID:
23827973
12.

Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.

Oh SY, Ju YT, Choi SK, Ha CY, Lee WS, Kim HG, Lee GW, Kwon HC, Kang JH.

Invest New Drugs. 2011 Oct;29(5):1050-6. doi: 10.1007/s10637-010-9409-3. Epub 2010 Mar 19.

PMID:
20238142
13.

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.

Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Kamijo A.

Oncology. 2015;88(6):353-9. doi: 10.1159/000369976. Epub 2015 Jan 9.

14.

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.

Shiozawa M, Akaike M, Sugano N, Tsuchida K, Yamamoto N, Morinaga S.

Cancer Chemother Pharmacol. 2010 Oct;66(5):987-92. doi: 10.1007/s00280-010-1278-0. Epub 2010 Jul 10.

PMID:
20623226
15.

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.

Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y.

Invest New Drugs. 2012 Aug;30(4):1690-6. doi: 10.1007/s10637-011-9743-0. Epub 2011 Sep 6.

PMID:
21894500
16.

Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.

Tsunoda A, Yasuda N, Nakao K, Narita K, Watanabe M, Matsui N, Kusano M.

Oncology. 2009;77(3-4):192-6. doi: 10.1159/000236017. Epub 2009 Sep 3.

PMID:
19729976
17.
18.

A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.

Ishida H, Miyake Y, Fukunaga M, Watanabe Y, Kato T, Takemoto H, Furukawa H.

Jpn J Clin Oncol. 2009 Sep;39(9):601-5. doi: 10.1093/jjco/hyp067. Epub 2009 Jun 17.

PMID:
19535386
19.

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.

Chon HJ, Rha SY, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HC.

Cancer Chemother Pharmacol. 2011 Oct;68(4):991-9. doi: 10.1007/s00280-011-1560-9. Epub 2011 Feb 16.

20.

Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.

Iwasa S, Yamada Y, Kato K, Goto A, Honma Y, Hamaguchi T, Shimada Y.

Anticancer Res. 2012 Sep;32(9):4157-61.

PMID:
22993378

Supplemental Content

Support Center